The chief of Samsung Biologics Co., the biotech arm of South Korea's Samsung Group, said Friday its new biomedicine ...

Samsung Biologics CEO John Lim reveals 5th factory completion plans for next month Joonrim Samba expands global presence with ...

Samsung is backing Alzheimer’s disease blood test developer C2N Diagnostics, with $10 million to help scale up its commercial ...

According to internal sources who requested anonymity, multiple global pharmaceutical clients are closely monitoring Samsung Biologics’ ongoing labor-management conflict and have explicitly expressed ...

Samsung Biologics, Hanmi Pharmaceutical Partner to Sell Prolia Biosimilar in Korea Samsung Bioepis and Hanmi Pharmaceutical ...

Samsung Biologics is planning more than 50 meetings with global big pharmaceutical companies at the upcoming DCAT Week 2025 in the United States, seeking to aggressively expand its network, the ...

A St. Louis-based company known for its work in Alzheimer's and neurological testing can expand its footprint, thanks to a $10 million investment from several life sciences companies.

The funds will go towards scaling C2N Diagnostics’ laboratory services and advancing the company’s range of diagnostic tests.

“Since Samsung C&T stepped into the life sciences industry by investing in biologics CDMO and biosimilar business, it has contributed to the stabilization of the biopharmaceutical supply chain ...